Buyer's Market

Current employment options favor companies as well as less-experienced workers.

Written byBetsy Alberty
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

The biotech industry has yet to recover fully from the boom and then bust of 2000-2001. Venture investment in biotech was $4.34 billion in 2000 but then dropped off for several years. Overall, it has started to pick up again, registering $4.18 billion in 2004 and $3.77 billion in 2005, according to a recent PricewaterhouseCoopers MoneyTree survey. Investment in the medical-device sector has also recently seen a reversal of a downward trend ($2.50 billion invested in 2000 followed by a drop, and rising again since 2004, registering $2.15 billion in 2005). Hiring follows investments by 6-12 months, however, and as a recruiter, I did not see a significant increase in hiring activity until late 2004-2005, when hiring focused on the growing areas of clinical and regulatory positions. Overall, hiring is still a buyer's (i.e., company's) market.

One result is a steadily increasing pool of highly experienced candidates who are being ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies